These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32706857)

  • 41. Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.
    Smith C; Brennan RM; Tey SK; Smyth MJ; Burrows SR; Miles JJ; Hill GR; Khanna R
    J Virol; 2016 Aug; 90(16):7497-507. PubMed ID: 27279616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients.
    Muheim C; Vogel G; Seydoux C; Gillet M; Mosimann F; Von Segesser L; Sahli R; Estrade C; van Melle G; Meylan PR
    Transplantation; 2002 Jul; 74(2):226-36. PubMed ID: 12151736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation.
    Emery VC; Asher K; Sanjuan Cde J
    J Clin Virol; 2012 Jun; 54(2):125-9. PubMed ID: 22445261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human cytomegalovirus: a survey of end-organ diseases and diagnostic challenges in solid organ transplant recipients.
    Contreras G; Ho D
    Curr Opin Organ Transplant; 2022 Aug; 27(4):243-249. PubMed ID: 36354249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients.
    Chou SW
    N Engl J Med; 1986 May; 314(22):1418-23. PubMed ID: 3010114
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human cytomegalovirus seroprevalence and titres in solid organ transplant recipients and transplant donors in Seoul, South Korea.
    La Y; Kwon DE; Yoo SG; Lee KH; Han SH; Song YG
    BMC Infect Dis; 2019 Nov; 19(1):948. PubMed ID: 31703564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C; Preiksaitis JK; Cervera C;
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
    Molina-Ortega A; Martín-Gandul C; Mena-Romo JD; Rodríguez-Hernández MJ; Suñer M; Bernal C; Sánchez M; Sánchez-Céspedes J; Pérez Romero P; Cordero E
    Clin Microbiol Infect; 2019 Jun; 25(6):753-758. PubMed ID: 30292792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
    Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
    J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes.
    Corrales I; Giménez E; Solano C; Amat P; de la Cámara R; Nieto J; Garcia-Noblejas A; Navarro D
    J Med Virol; 2015 Feb; 87(2):248-55. PubMed ID: 25132583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients.
    Wang N; Athans V; Neuner E; Bollinger J; Spinner M; Brizendine K
    Transpl Infect Dis; 2018 Dec; 20(6):e12991. PubMed ID: 30184302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
    Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
    Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.
    Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
    Transplantation; 2015 Jun; 99(6):1186-91. PubMed ID: 25489844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of highly sensitive nucleic acid amplification testing for plasma cytomegalovirus DNA load in diagnosis of cytomegalovirus gastrointestinal disease among kidney transplant recipients.
    Taksinwarajarn T; Sobhonslidsuk A; Kantachuvesiri S; Thongprayoon C; Cheungpasitporn W; Bruminhent J;
    Transpl Infect Dis; 2021 Aug; 23(4):e13635. PubMed ID: 33982825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
    Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
    J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C; Preiksaitis J; Cervera C;
    Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
    Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
    New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.